



ASX/Media Release

Benitec Chosen to Present at BioEquity Europe 2011, May 23, Paris, France

4 May 2011, Melbourne, Australia: Benitec Ltd (ASX:BLT) a world leader in gene silencing for human therapeutics, is pleased to announce that its Chief Executive Officer, Dr Peter French has been invited to present at BioEquity Europe 2011 on May 23-25 in Paris (for details, please refer to <http://www.biocentury.com/Conferences>).

BioEquity is an annual invitation-only boutique conference for investors, pharmaceutical companies and executives working in the life sciences sector in Europe and globally. Dr French's presentation is scheduled for 12:00 CET on Monday May 23, in room La Seine C.

Benitec's presentation will highlight the relaunch of the company following the 2010 decision of the US Patent and Trademark Office (USPTO) Board of Appeal to reinstate the Company's foundational Graham patent for the use of DNA-directed RNA interference (ddRNAi) for the development of human therapeutics, and a fully underwritten AU\$8 million capital raising, announced earlier this month. Dr French will present Benitec's in-house programs in cancer and infectious disease as well collaborative opportunities for its ddRNAi platform.

Benitec's BioEquity presentation will be issued to the Australian Stock Exchange and will also be available on www.benitec.com on the same day.

Dr French has also been invited to participate in a panel discussion entitled "Leadership: What's the DNA of today's CEO?" to be held on Tuesday, May 24 from 10-11:15 CET.

Benitec's Chairman, Mr Peter Francis who will accompany Dr French at BioEquity said, "The invitation to present at BioEquity is timely for Benitec as it underlines the Company's renewed intent to become a significant player in the global life sciences industry. We look forward to continuing the momentum Benitec is gaining."

Prior to BioEquity, Dr French and Mr Francis will be meeting with industry partners and investors in the United States and the UK, as part of a roadshow to showcase the new Benitec era. He will be joined by Directors Dr John Chiplin (US) and Mr Iain Ross (UK).

About Benitec www.benitec.com

Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian stock exchange under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.

For Further Information

Dr Peter French
Chief Executive Officer
Tel: +61 (0)412 457 595

pfrench@benitec.com

Media enquiries:
College Hill Life Sciences
Sue Charles (Global)
Daniel Gooch (Europe)
Tel: +44 (0)20 7866 7866

benitec@collegehill.com

Andrew Geddes (Australia)
Tel: +61 (0)408 677 734

Rebecca Skye Dietrich (US)
Tel: +1 (857) 241 0795